Optimi Health is a British Columbia manufacturer that already ships finished MDMA and botanical psilocybin into regulated channels, yet the Nasdaq listing did not turn that license stack into a growing commercial book. The company raised $15 million in a May offering that listed the shares on the Nasdaq Capital Market under this ticker, after a reverse split designed to clear the exchange price screen. Cash replaced a near-empty treasury, but the same season that closed the offering still showed customers in Australia working through earlier lots rather than pulling fresh export volume. The investment debate is whether licensed capacity and a new United States listing are a platform, or whether they are a costly wrapper around a still-tiny prescription franchise.
Nine-month revenue fell to about $240 thousand Canadian as in-market inventory covered demand that used to require new shipments. The same window produced a loss near $6 million Canadian, with investor-relations spend tied to the listing now larger than product sales. Cash stood near $13 million Canadian at mid-year, which is the entire recapitalization story in one line. The plant in Princeton is real, the Drug Establishment Licence is real, and the Mind Medicine Australia channel is real. None of those facts yet show up as a scaling top line.
Management states cash and expected receipts cover obligations for twelve months from the mid-year statements. That runway clock now sits next to a $100 million equity line with Seven Knots that is not yet available to draw because the resale registration is still pending. The next test is whether Australian authorized-prescriber volumes refill the export book, or whether the listing simply financed a longer wait. Does prescription throughput recover before the equity line, or the related-party paper, becomes the residual claim's main story?